|Bid||1,290.00 x 175400|
|Ask||1,310.00 x 417900|
|Day's range||1,287.83 - 1,300.83|
|52-week range||1,270.00 - 1,724.50|
|PE ratio (TTM)||27.38|
|Earnings date||7 Feb 2018|
|Forward dividend & yield||1.01 (5.14%)|
|1y target est||1,549.93|
Harvey Jones reckons Bunzl plc (LON: BNZL) could fly back into favour before fellow struggler GlaxoSmithKline plc (LON: GSK).
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled it will look to speed development of an experimental cancer treatment as part of its ambition to expand in oncology just two years after selling ...
Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. Senior executives in the financial services sector, which accounts for about 12 percent of the economy, told Reuters May's efforts to secure a transition deal had come too late and they had no choice but to start restructuring.
LONDON, Dec (Shanghai: 600875.SS - news) 7 (Reuters) - Big companies are stepping up their plans in case Britain crashes out of the European Union without a deal as Prime Minister Theresa May struggles to get talks back on track after a major setback. Britain is aiming to agree with the EU on Dec. 14 to move the Brexit talks on to the second phase. This would focus on trade and a two-year transition deal to smooth the departure after March 2019.
Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...
GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.
Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy plans after Brexit. The move is welcome news for Prime Minister Theresa May, who has struggled to win over large sections of industry as Britain prepares to leave the European Union. Thanks to the strength of UK universities and the presence of two major pharmaceuticals companies in GlaxoSmithKline and AstraZeneca, the drugs industry has been a bright spot in the British economy for many years.
Britain won a vote of confidence from its economically important life sciences sector on Wednesday as several major drug companies committed to invest in the country under the government's industrial strategy ...
GSK acquired Novartis' portfolio of Voltaren products in 2016 and has been responsible for marketing and selling them since then
GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. and AstraZeneca Plc are among more than two dozen global pharmaceutical companies pledging to invest funds in the U.K. as part of a multi-billion-pound ...
The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated". "We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.
The Australian Competition and Consumer Commission on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations ...
GlaxoSmithKline is using artificial intelligence to learn why certain HIV patients drop out of treatment. "The only clues that exist are in unstructured types of data," such as doctor's notes, ...
GlaxoSmithKline’s (GSK) Vaccines segment reported revenues of ~1.7 billion pounds during 3Q17, reflecting 5.0% growth in revenues compared to 3Q16.
GlaxoSmithKline's (GSK) 3Q17 revenues of ~7.8 billion pounds represented 4.0% growth compared to its 3Q16 revenues of ~7.5 billion pounds.
In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.
The FTSE fell on Friday at the end of a choppy session that saw Britain's top-share index accelerate losses and join a global risk-off move following reports in the United States that raised new worries over the stability of Donald Trump's administration. The FTSE fell 0.4 percent, having earlier gained as much as 0.4 percent thanks to a pull back in the pound that helped it recover from the losses seen in morning trade. ABC News reported that former U.S. national security adviser Michael Flynn was prepared to testify that Trump directed him to make contact with Russians when he was a presidential candidate.
The FTSE fell on Friday at the end of a choppy session that saw Britain's top-share index accelerate losses and join a global risk-off move following reports in the United States that raised new worries ...
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.